U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07054255) titled 'Bioequivalence Study of Ranolazine Extended-release Tablets in Healthy Chinese Subjects' on June 27.
Brief Summary: The present study was conducted with the objective of comparing the bioequivalence and safety of a single dose of ranolazine extended-release tablets (Test product) manufactured by Haisco Pharmaceutical Group Co., Ltd. with those of the reference product (Ranexa(R), Gilead Sciences, Inc.) in Chinese healthy subjects under fasting and fed conditions
Study Start Date: Sept. 06, 2020
Study Type: INTERVENTIONAL
Condition:
Healthy
Intervention:
DRUG: Test formulation (Ranolazine extended-release tablets)
A single oral...